Michael Gelband’s Revolution Medicines RVMD Stock Holding History

Michael Gelband’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.24M	Buy	44,020 +33,484	+318%	+$4.89M	0.05%	346
2026 Q1	$1.02M	Buy	+10,536	New	+$1.06M	0.01%	989
2025 Q4	–	Sell	-31,591	Closed	-$1.48M	–	1995
2025 Q3	$1.48M	Sell	31,591 -39,599	-56%	-$1.55M	0.02%	832
2025 Q2	$2.62M	Buy	71,190 +60,839	+588%	+$2.34M	0.02%	641
2025 Q1	$366K	Sell	10,351 -112,964	-92%	-$4.59M	﹤0.01%	1189
2024 Q4	$5.39M	Buy	+123,315	New	+$6.22M	0.04%	427
2024 Q1	–	Sell	-39,719	Closed	-$1.14M	–	1904
2023 Q4	$1.14M	Sell	39,719 -112,571	-74%	-$2.7M	0.01%	769
2023 Q3	$4.21M	Buy	+152,290	New	+$4.52M	0.04%	418
2022 Q4	–	Sell	-38,676	Closed	-$763K	–	2061
2022 Q3	$763K	Sell	38,676 -90	-0.2%	-$1.98K	0.01%	1216
2022 Q2	$756K	Buy	38,766 +16,579	+75%	+$323K	0.01%	1194
2022 Q1	$566K	Buy	22,187 +11,961	+117%	+$260K	0.01%	1455
2021 Q4	$257K	Buy	+10,226	New	+$288K	﹤0.01%	1717
2021 Q2	–	Sell	-8,662	Closed	-$397K	–	2740
2021 Q1	$397K	Sell	8,662 -5,172	-37%	-$232K	0.01%	1504
2020 Q4	$548K	Buy	+13,834	New	+$547K	0.01%	1187

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Michael Gelband's RVMD Position: Q2 2026 in Review

Michael Gelband increased its Revolution Medicines (RVMD) stake by 318% in Q2 2026, buying an estimated $4.89M and bringing the position to 44,020 shares worth $8.24M. The position accounts for 0.05% of the portfolio, ranked #346.

Michael Gelband first reported a position in RVMD in Q4 2020 and has held it in 14 quarters since. 688 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

Michael Gelband held 44,020 shares of Revolution Medicines worth $8.24M as of Q2 2026.
Michael Gelband bought 33,484 Revolution Medicines shares in Q2 2026, an estimated $4.89M.
Revolution Medicines made up 0.05% of Michael Gelband's portfolio in Q2 2026, its #346 holding.
Michael Gelband first reported a position in Revolution Medicines in Q4 2020 and has held it in 14 quarters since.
688 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.